HD Biosciences Co., Ltd (HDB) and Anchor Therapeutics, Inc. today announced that they have formed a strategic collaboration to co-develop and co-market Anchorí»s proprietary pepducin technology and provide novel drug development solutions to global pharmaceutical companies with drug discovery efforts focused on G-protein coupled receptors (GPCR).
HD Biosciences, a leading biology-focused Contract Research Organization (CRO) in Shanghai, announces that the company has signed another multiple FTE based agreement on medicinal chemistry with a global leading pharmaceutical company to support their new lead candidate development.
HD Biosciences Co., a leader in plate-based pharmacology and biology focused contract research organization (CRO), announced that the companyí»s HTS and SAR platforms achieved 5 million data points from the services provided to pharmaceutical and biotech partners.
HD Biosciences announces the full implementation of target identification & validation platform which won a major agreement with its partner on Adeno-Associated Virus (AAVs) based technology application on drug discovery. The agreement is focused on isogenic human disease models and sequential pharmacology research which will assist client in their decision on portfolio development.